Private Advisory Group LLC acquired a new position in Twist Bioscience Corporation (NASDAQ:TWST – Free Report) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 7,934 shares of the company’s stock, valued at approximately $1,533,000.
Several other institutional investors have also recently added to or reduced their stakes in the business. Russell Investments Group Ltd. boosted its holdings in shares of Twist Bioscience by 190.8% in the 3rd quarter. Russell Investments Group Ltd. now owns 283,910 shares of the company’s stock valued at $54,863,000 after buying an additional 186,294 shares during the period. Pier 88 Investment Partners LLC bought a new stake in shares of Twist Bioscience during the 3rd quarter valued at about $676,000. Lisanti Capital Growth LLC bought a new stake in shares of Twist Bioscience during the 3rd quarter valued at about $5,584,000. Ritholtz Wealth Management acquired a new stake in Twist Bioscience during the third quarter worth about $327,000. Finally, Lido Advisors LLC acquired a new stake in Twist Bioscience during the third quarter worth about $8,162,000.
Twist Bioscience Price Performance
Twist Bioscience stock opened at $111.60 on Monday. The company has a 50-day simple moving average of $150.23 and a 200-day simple moving average of $93.07. The firm has a market capitalization of $7.00 billion, a P/E ratio of -53.40 and a beta of 2.25. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.38 and a current ratio of 2.67. Twist Bioscience Corporation has a one year low of $23.30 and a one year high of $219.71.
Twist Bioscience (NASDAQ:TWST – Get Free Report) last issued its quarterly earnings data on Thursday, November 12th. The company reported ($0.32) earnings per share for the quarter, beating the consensus estimate of ($0.39) by $0.07. The firm had revenue of $126.64 million for the quarter, compared to the consensus estimate of $123.55 million. Twist Bioscience had a negative net margin of 28.34% and a negative return on equity of 27.53%. The firm’s quarterly revenue was up 26.7% on a year-over-year basis. As a group, equities analysts expect that Twist Bioscience Corporation will post -1.52 earnings per share for the current year.
Wall Street Analysts Forecast Growth
A number of equities analysts have issued reports on TWST shares. Robert W. Baird cut their target price on shares of Twist Bioscience from $187.00 to $135.00 and set an “outperform” rating on the stock in a report on Friday. Leerink Partners lowered their target price on Twist Bioscience from $190.00 to $175.00 and set an “outperform” rating for the company in a report on Friday. TD Cowen dropped their price target on Twist Bioscience from $190.00 to $137.00 and set a “buy” rating on the stock in a research report on Friday. UBS Group started coverage on Twist Bioscience in a report on Wednesday, September 9th. They issued a “neutral” rating and a $144.00 price target on the stock. Finally, BWS Financial reissued a “sell” rating and issued a $45.00 price target on shares of Twist Bioscience in a report on Friday, September 18th. Seven equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $141.00.
Check Out Our Latest Stock Report on TWST
Insider Buying and Selling
In other Twist Bioscience news, SVP Paula Green sold 1,007 shares of the firm’s stock in a transaction that occurred on Tuesday, November 3rd. The shares were sold at an average price of $135.40, for a total value of $136,347.80. Following the sale, the senior vice president owned 105,625 shares in the company, valued at approximately $14,301,625. This trade represents a 0.94% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CAO Robert Werner sold 1,482 shares of Twist Bioscience stock in a transaction that occurred on Friday, October 2nd. The shares were sold at an average price of $188.88, for a total value of $279,920.16. Following the sale, the chief accounting officer directly owned 42,917 shares in the company, valued at approximately $8,106,162.96. This trade represents a 3.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 495,279 shares of company stock valued at $80,489,387 in the last ninety days. Insiders own 3.08% of the company’s stock.
Twist Bioscience Profile
Twist Bioscience Corporation is a biotechnology company that uses a silicon-based platform to manufacture synthetic DNA. Its technology supports the production of many DNA sequences in parallel for research and commercial applications. The company provides synthetic genes, gene fragments and oligonucleotide pools, as well as tools for next-generation sequencing, including target-enrichment products. Through its biopharma business, Twist also offers antibody discovery and related services to support the development of therapeutics.
Read More
- Five stocks we like better than Twist Bioscience
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
Want to see what other hedge funds are holding TWST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Twist Bioscience Corporation (NASDAQ:TWST – Free Report).
Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
